The CXCR3 Chemokine System in Cancer Immunotherapy
Description: PROJECT NARRATIVE Immune checkpoint blockade therapy for cancer can result in durable clinical responses; however, it is only effective in a fraction of patients. Improving the efficacy of cancer immunotherapy will require a better understanding of the molecules that control the complex interactions of immune cells in the tumor microenvironment required for effective therapy, and their regulation by checkpoint blockade. This project will study how the chemokine receptor CXCR3 and its ligands, CXCL9 and CXCL10, contribute in critical ways to efficacy of checkpoint blockade immunotherapy, and how to use this knowledge to harness the potential of this approach to benefit more cancer patients.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2016-12-01
End date: 2023-05-31
Investigator: ANDREW D LUSTER (lead)
Institution: Massachusetts General Hospital
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 15
Funder award ID: R01CA204028
OpenAlex ID: G8554189727
